Baseline patient characteristics and previous treatments
| Characteristic . | No. . | % . |
|---|---|---|
| Baseline | (n = 50) | |
| Sex | ||
| Male | 52 | |
| Female | 48 | |
| Age, years | ||
| Median at diagnosis (range) | 58.8 (38.1-73.5) | |
| Median at sampling (range) | 65.5 (44.7-85.3) | |
| Median time from initial treatment to sampling, years (range) | 4.8 (1.4-13.8) | |
| Heavy chain | ||
| IgG | 60 | |
| IgA | 22 | |
| Light chain disease | 18 | |
| Light chain | ||
| κ | 66 | |
| λ | 34 | |
| Median hemoglobin, g/dL (range) | 10.6 (7.0-14.6) | |
| Median No. of thrombocytes per microliter (range) | 104.0 (15.0-302.0) | |
| Median LDH, U/L (range) | 230.5 (124.0-2294.0) | |
| Median GFR, mL/min (range) | 69.4 (8.0-148.0) | |
| Salmon and Durie stage at diagnosis | ||
| IIA | 6 | |
| IIB | 0 | |
| IIIA | 78 | |
| IIIB | 16 | |
| Cytogenetic analyses performed | 78 | |
| Cytogenetic aberrations | (n = 39) | |
| Gain 1q21 (>2 copies) | 62 | |
| Deletion 17p | 33 | |
| t(4;14) | 13 | |
| t(14;16) | 8 | |
| At previous treatments | (n = 50) | |
| Median No. of previous lines of therapy (range) | 5 (2-15) | |
| Prior exposure class | ||
| PI | 100 | |
| IMiD | 100 | |
| Cytotoxic agent | 94 | |
| HDT | 90 | |
| Prior exposure agent | ||
| Bortezomib | 100 | |
| Carfilzomib | 18 | |
| Thalidomide | 34 | |
| Lenalidomide | 100 | |
| Pomalidomide | 48 | |
| Refractory class | ||
| PI | 76 | |
| IMiD | 88 | |
| PI + IMiD | 66 | |
| Refractory agent | ||
| Bortezomib | 72 | |
| Carfilzomib | 16 | |
| Thalidomide | 14 | |
| Lenalidomide | 82 | |
| Pomalidomide | 40 | |
| PD prior to sampling | 82 | |
| Refractory to last therapy | 78 | |
| Refractory to last therapy agent | (n = 39) | |
| Bortezomib | 33 | |
| Carfilzomib | 13 | |
| Lenalidomide | 20 | |
| Pomalidomide | 23 | |
| Bendamustine | 8 | |
| Monoclonal CD38 antibody | 3 | |
| Characteristic . | No. . | % . |
|---|---|---|
| Baseline | (n = 50) | |
| Sex | ||
| Male | 52 | |
| Female | 48 | |
| Age, years | ||
| Median at diagnosis (range) | 58.8 (38.1-73.5) | |
| Median at sampling (range) | 65.5 (44.7-85.3) | |
| Median time from initial treatment to sampling, years (range) | 4.8 (1.4-13.8) | |
| Heavy chain | ||
| IgG | 60 | |
| IgA | 22 | |
| Light chain disease | 18 | |
| Light chain | ||
| κ | 66 | |
| λ | 34 | |
| Median hemoglobin, g/dL (range) | 10.6 (7.0-14.6) | |
| Median No. of thrombocytes per microliter (range) | 104.0 (15.0-302.0) | |
| Median LDH, U/L (range) | 230.5 (124.0-2294.0) | |
| Median GFR, mL/min (range) | 69.4 (8.0-148.0) | |
| Salmon and Durie stage at diagnosis | ||
| IIA | 6 | |
| IIB | 0 | |
| IIIA | 78 | |
| IIIB | 16 | |
| Cytogenetic analyses performed | 78 | |
| Cytogenetic aberrations | (n = 39) | |
| Gain 1q21 (>2 copies) | 62 | |
| Deletion 17p | 33 | |
| t(4;14) | 13 | |
| t(14;16) | 8 | |
| At previous treatments | (n = 50) | |
| Median No. of previous lines of therapy (range) | 5 (2-15) | |
| Prior exposure class | ||
| PI | 100 | |
| IMiD | 100 | |
| Cytotoxic agent | 94 | |
| HDT | 90 | |
| Prior exposure agent | ||
| Bortezomib | 100 | |
| Carfilzomib | 18 | |
| Thalidomide | 34 | |
| Lenalidomide | 100 | |
| Pomalidomide | 48 | |
| Refractory class | ||
| PI | 76 | |
| IMiD | 88 | |
| PI + IMiD | 66 | |
| Refractory agent | ||
| Bortezomib | 72 | |
| Carfilzomib | 16 | |
| Thalidomide | 14 | |
| Lenalidomide | 82 | |
| Pomalidomide | 40 | |
| PD prior to sampling | 82 | |
| Refractory to last therapy | 78 | |
| Refractory to last therapy agent | (n = 39) | |
| Bortezomib | 33 | |
| Carfilzomib | 13 | |
| Lenalidomide | 20 | |
| Pomalidomide | 23 | |
| Bendamustine | 8 | |
| Monoclonal CD38 antibody | 3 | |
Laboratory values at the time of sampling are shown.
GFR, glomerular infiltration rate; HDT, high-dose therapy; IgG, immunoglobulin G; LDH, lactate dehydrogenase; PD, progressive disease.